2025
Filter by topic
02-Oct-25
Convatec announces pricing of $500 Million 5.300% Senior Notes due 2035
Corporate01-Oct-25
Convatec announces plans to invest more than $1 billion in R&D facilities – major expansions in the US and UK
Corporate29-Sep-25
Convatec announces offering of Senior Notes
Corporate22-Sep-25
Convatec secures regulatory approval for ConvaMatrix™ in UK and Europe, supporting more patients with pioneering skin substitute technology
Corporate Advanced Wound Care02-Sep-25
Convatec strengthens Leadership Team to support growth
Corporate Advanced Wound Care20-Aug-25
Convatec commences share buyback programme
Corporate04-Aug-25
Update regarding Chief Executive Officer
Corporate29-Jul-25
Interim results for the six months ended 30 June 2025
Corporate Financial Performance24-Jul-25
Convatec secures US and European regulatory clearance for Aquacel™ ConvaFiber™ wound care innovation
Corporate Advanced Wound Care15-Jul-25
Convatec responds to CMS draft payment proposal for skin substitutes in the United States
Corporate Advanced Wound Care01-Jul-25
Comment on CMS proposed rule change issued 30 June 2025
Corporate Continence Care Ostomy Care26-Jun-25
Convatec welcomes regulatory approval of subcutaneous apomorphine infusion for advanced Parkinson’s disease in the US
Corporate Infusion Care22-May-25
AGM trading update for the four months ended 30 April 2025
Corporate Financial Performance20-May-25
Advancing subcutaneous infusion therapy for patients through innovation and partnerships
Corporate Infusion Care25-Apr-25
Convatec receives regulatory approval for ConvaNiox™
Corporate Advanced Wound Care11-Apr-25
Convatec welcomes postponement of Local Coverage Determinations (LCDs) on skin substitutes until January 2026
Corporate Advanced Wound Care